---
title: "In the first quarter, SSY GROUP's profit attributable to shareholders decreased by approximately 59.5% year-on-year to about HKD 168 million"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/242545500.md"
description: "SSY GROUP announced its Q1 2025 performance, with profit attributable to shareholders decreasing by approximately 59.5% year-on-year to about HKD 168 million, revenue decreasing by 36.9% year-on-year to about HKD 1.136 billion, and gross profit decreasing by 50.6% year-on-year to about HKD 509 million. It is expected that profit attributable to shareholders will decline by approximately 45% to 60% year-on-year in the first half of 2025. The decline in performance is mainly due to factors such as the impact of the flu epidemic, medical insurance cost control, the expansion of volume-based procurement, and intensified industry competition"
datetime: "2025-05-30T09:11:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/242545500.md)
  - [en](https://longbridge.com/en/news/242545500.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/242545500.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/242545500.md) | [English](https://longbridge.com/en/news/242545500.md)


# In the first quarter, SSY GROUP's profit attributable to shareholders decreased by approximately 59.5% year-on-year to about HKD 168 million

According to the Zhitong Finance APP, SSY GROUP (02005) announced its performance for the first quarter of 2025, with revenue decreasing by 36.9% year-on-year to approximately HKD 1.136 billion, mainly due to a decline in the sales of intravenous infusions and the unaudited revenue of ampoule injections. Gross profit decreased by 50.6% year-on-year to approximately HKD 509 million, with a gross profit margin of about 44.8% (compared to approximately 57.3% in the same period of 2024). Shareholders' profit attributable to the company decreased by approximately 59.5% year-on-year to about HKD 168 million.

In addition, the group expects that the profit attributable to equity holders for the first half of 2025 will decrease by approximately 45% to 60% year-on-year.

The announcement stated that the decline in interim performance was mainly due to the following factors leading to a drop in unaudited revenue: In the first quarter of 2024, a domestic flu outbreak led to strong demand for intravenous infusions and other pharmaceuticals, but there has been no large-scale epidemic in the country so far in 2025, coupled with the impact of medical insurance cost control on the growth of terminal drug sales; the expansion of various forms of volume-based procurement (including national centralized procurement and local alliance procurement) and intensified domestic and international industry competition have brought continuous price pressure; and it is expected that the revenue of bromhexine hydrochloride ampoule injections in the first half of 2025 will decrease compared to the same period in 2024

### 相關股票

- [SSY GROUP (02005.HK)](https://longbridge.com/zh-HK/quote/02005.HK.md)

## 相關資訊與研究

- [SSY Group Profit Halves as Revenue and Margins Slide in Challenging 2025](https://longbridge.com/zh-HK/news/280725971.md)
- [SSY Group Wins China Approval for Upadacitinib Bulk Drug](https://longbridge.com/zh-HK/news/281103720.md)
- [CSC Financial Sticks to Their Buy Rating for Longfor Group Holdings (LNGPF)](https://longbridge.com/zh-HK/news/280898279.md)
- [Longfor Group Holdings (LNGPF) Gets a Buy from CICC](https://longbridge.com/zh-HK/news/280899756.md)
- [CICC Sticks to Its Buy Rating for C&D International Investment Group Ltd. (1908)](https://longbridge.com/zh-HK/news/280899096.md)